David Chiswell, Ph.D. – Chairman

Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP

David Chiswell, Ph.D. has over 30 years' experience in the biotechnology industry. In 1990, Dr. Chiswell co-founded Cambridge Antibody Technology (CAT) and served as its CEO from 1996 to 2002. He has served as CEO of Kymab Ltd from 2015 to 2018 and prior to that as CEO of Nabriva Therapeutics from 2009 to 2012. He has served as a director of Arakis and non-executive chairman of Sosei, Arrow Therapeutics, Daniolabs, Nabriva Therapeutics and Kymab.

Dr. Chiswell is a past chairman of the UK BioIndustry Association (BIA) and his contributions to the field were recognized in 2006 when he was awarded the OBE by HM the Queen for services to the biotechnology industry. In addition to being chairman of Albireo, he also currently serves as chairman of Epsilogen and a board member of Avillion Bond 2 Development 2 GP.

Team members

David Chiswell, Ph.D. – Chairman

Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP

Anne Klibanski, M.D.

President and CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Michael Gutch, Ph.D.

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Roger A. Jeffs, Ph.D.

Former President and co-CEO, United Therapeutics

Stephanie S. Okey, M.S.

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Davey S. Scoon

Former CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors

Ron Cooper

President and Chief Executive Officer